Health knowledge made personal
WellPage for Bacillus Anthracis Treatment
+ Bookmark › Share
Go
Search posts:

Bacillus Anthracis Treatment - Articles

Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities by nih.gov Posted Thu 20 Oct 2011 8:00pm Description of Invention: Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attract ... Read on »
Methods for Preparing Bacillus anthracis Protective Antigen for Use in Vaccines by nih.gov Posted Sun 31 Aug 2008 5:00pm Description of Invention: This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) from a cell or organism, particularly a recombinant cell or microorganism, for use in vaccines. Production and purification methods of modified PA from a non-sporogenic strain of Bacillus anthracis are d ... Read on »
Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines by nih.gov Posted Sun 31 Aug 2008 5:00pm Description of Invention: This invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines. PA is a secreted, non-toxic protein with a molecular weight of 83 KDa. PA is a major component of the currently licensed human vaccine (Anthrax Vaccine Adsorbed, AVA). Although the l ... Read on »
gammaPGA Conjugates for Eliciting Immune Responses Directed Against Bacillus anthracis and Other Bacilli by nih.gov Posted Sun 31 Aug 2008 5:00pm Description of Invention: This invention claims immunogenic conjugates of a poly-gamma-glutamic acid (gammaPGA) of B. anthracis, or of another bacillus that expresses a gammaPGA that elicit a serum antibody response against B. anthracis, in mammalian hosts to which the conjugates are administered. The invention also relates m ... Read on »
Improved Bacterial Host for Production of Anthrax Toxin Proteins and Vaccines: Bacillus anthracis BH450 by nih.gov Posted Sun 31 Aug 2008 5:00pm Description of Invention: Anthrax toxin has previously been made from various avirulent strains of Bacillus anthracis. The inventors have genetically engineered a new strain of B. anthracis with improved properties. The strain, designated BH450, is totally deficient in the ability to make spores and to produce a major extrac ... Read on »
Monoclonal Antibodies That React With the Capsule of Bacillus anthracis by nih.gov Posted Sun 30 Aug 2009 5:00pm Description of Invention: Bacillus anthracis is the causative agent of anthrax and is surrounded by a polypeptide capsule of poly-gamma-D-glutamic acid (gammaDPGA). gammaDPGA is poorly immunogenic and has antiphagocytic properties. The bacterial capsule is essential for virulence. Antibodies to the capsule have been shown t ... Read on »
Draft Guidance for Industry and Food and Drug Administration Staff - Class II Special Controls Guidance Document: In Vitro Diagn by FDA Posted Wed 18 May 2011 12:00am DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: May 18, 2011. You should submit comments and suggestions regarding this draft document within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Su ... Read on »
Raxibacumab Approved for Inhalational Anthrax by HealthFinder Posted Fri 14 Dec 2012 12:00pm healthnewslink Neutralizes anthrax toxins, which can kill FRIDAY, Dec. 14 (HealthDay News) -- Raxibacumab i ... Read on »
PLANT vs. PATHOGEN: Enlisting Tobacco in the Fight Against Anthrax by Environmental Health Posted Wed 31 May 2006 9:00pm PLANT vs. PATHOGEN: Enlisting Tobacco in the Fight Against Anthrax Formal Correction: This article has been formally corrected to address the following errors. Jump to ... Read on »
My submission to the Presidential Commission for the Study of Bioethical Issues by Meryl Nass Posted Fri 03 Feb 2012 11:09am Public Commentary -- for meeting on February 2-3, 2012 Presidential Commission for the Study of Bioethical Issues 1425 New York Avenue NW, Suite C–100 Washington, DC 20005 info@bioethics.gov     Re:  Pediatric anthrax vaccine trial     Dear Members of the Presidential Commission for the Study of Bioethical Issues:   In this statement, I w ... Read on »